Androgen receptor expression is associated with a distinct low-proliferative phenotype in triple-negative breast cancer
This study demonstrates that androgen receptor expression in triple-negative breast cancer defines a distinct, low-proliferative molecular subtype characterized by specific genomic alterations, enhanced TGFβ signaling, and a unique immune microenvironment, although it does not independently predict patient survival.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Breast cancer is not a single disease but a collection of different conditions that happen to share a name. Within the most aggressive form, known as triple-negative breast cancer, the cells lack three common receptors that doctors usually target with medication. This leaves the disease difficult to treat and often dangerous. However, scientists have long known that even within this aggressive group, there are different biological flavors. Some cells behave like a specific type of sweat gland cell, a feature called apocrine differentiation, and these cells often carry a receptor for a hormone called androgen. While researchers have known for years that these androgen-positive cells exist, they have not fully understood what makes them tick or how they differ from the rest of the tumor at the most basic level. The question remains whether the presence of this single receptor changes the behavior of the cancer cells themselves or if it is merely a marker for a different type of tumor.
A team of researchers set out to answer this by looking at the genetic instructions inside thousands of breast cancer tumors. They gathered data from four large groups of patients, totaling over a thousand cases, and also examined the genetic activity of individual cells from twenty-seven patients. Instead of just looking at the tumor as a whole, they zoomed in to see which specific cells were carrying the androgen receptor and what those cells were doing compared to their neighbors. They found that tumors with high levels of this receptor were biologically distinct. These tumors tended to be less aggressive in their growth patterns, carrying fewer mutations in a critical gene that usually causes cancer to run wild, and they showed a different mix of immune cells surrounding them.
The study revealed that the presence of the androgen receptor is not just a label but a sign of a specific, slower-moving state within the cancer. When the researchers looked at individual cells, they saw that the ones with the receptor were spending more time in a resting phase of their life cycle and less time dividing. In contrast, the cells without the receptor were actively preparing to split and multiply. This difference was consistent across all the large groups of patients they studied. Tumors with high levels of the receptor also showed a different genetic signature, with fewer errors in their DNA repair mechanisms and a higher frequency of a specific mutation that is often found in less aggressive cancers.
Beyond the cancer cells themselves, the environment surrounding the tumor also changed based on the receptor's presence. The researchers discovered that tumors with high androgen levels had a different immune landscape. They contained fewer of the immune cells that typically attack cancer directly and more of a type of immune cell that often helps tumors hide from the body's defenses. This shift was linked to increased activity in a signaling pathway known to calm down cell growth and alter how cells talk to one another. The data suggested that the androgen receptor might be turning on a set of instructions that slows the cancer down while simultaneously changing the neighborhood of the tumor to be less hostile to the cancer's survival.
Despite these clear biological differences, the study found that the presence of the androgen receptor did not guarantee a longer life for the patients in the groups they analyzed. While the tumors behaved in a calmer, less frantic way, this did not always translate into a measurable survival advantage in the data available. This suggests that while the receptor identifies a unique type of cancer cell with a slower pace, other factors likely influence the final outcome for the patient. The researchers noted that their work was based on analyzing genetic data from existing records and computer models, so the exact mechanisms behind these changes still need to be confirmed in a laboratory setting.
The findings offer a clearer picture of the diversity within triple-negative breast cancer. By identifying a subset of tumors that are biologically distinct, slower to divide, and surrounded by a specific immune environment, the study helps explain why some of these aggressive cancers might behave differently than others. It suggests that the androgen receptor is a key to understanding a specific, low-growth version of the disease, even if it does not yet provide a definitive cure or a guaranteed path to better survival. This distinction could eventually help doctors tailor treatments more precisely, recognizing that not all triple-negative breast cancers are the same, even when they look similar under a microscope.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.